| Daniel Enrique Parker Schmidt, | |
|
2120 Cienaga St, Oceano, CA 93445-9016 | |
| (805) 994-2100 | |
| (805) 994-2195 |
| Full Name | Daniel Enrique Parker Schmidt |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 2120 Cienaga St, Oceano, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518734821 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 108562 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Enrique Parker Schmidt, 2120 Cienaga St, Oceano, CA 93445-9016 Ph: (805) 994-2100 | Daniel Enrique Parker Schmidt, 2120 Cienaga St, Oceano, CA 93445-9016 Ph: (805) 994-2100 |
News Archive
LUMEDX Corporation, a leading provider of integrated cardiovascular information systems (CVIS), today announced the release of a new and complimentary educational Webinar on CD, The Power of Analytics: Managing Cath Lab Growth in Real Time.
A report by the conservative Heritage Foundation recommends making wealthier Medicare beneficiaries pay more to help get the program's "fiscal house in order." Also in the news, The Wall Street Journal reports that a judge who considers cases related to the Social Security Disability Insurance Program - one of the federal governments most rapidly growing entitlement programs - was placed on paid leave while complaints about his demeanor are probed.
Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
Researchers in Spain have demonstrated that studying the hypoxia signaling pathway could provide opportunities for treating coronavirus disease 2019 (COVID-19).
Response Biomedical Corporation announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company's diagnostic products, expanding its strategic presence in this important global market.
› Verified 2 days ago